CoChat

Cerebrolysin decreases amyloid‐β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease

Rockenstein, Edward, Torrance, Magdalena, Mante, Michael, Adame, Anthony, Paulino, Amy, Rose, John B., Crews, Leslie, Moessler, Herbert, Masliah, Eliezer · 2006 · Journal of Neuroscience Research
Cited by 88

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). We have previously shown in an amyloid protein precursor (APP) transgenic (tg) mouse model of AD‐like neuropathology that Cerebrolysin ameliorates behavioral deficits, is neuroprotective, and decreases amyloid burden; however, the mechanisms involved are not completely clear. Cerebrolysin might reduce amyloid deposition by regulating amyloid‐β (Aβ) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full‐length (FL) APP and its fragments, β‐secretase (BACE1), and Aβ‐degrading enzymes [neprilysin (Nep) and insulin‐degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C‐terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin‐dependent kinase‐5 (CDK5) and glycogen synthase kinase‐3β [GSK‐3β; but not stress‐activated protein kinase‐1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD‐like pathology in the APP tg mice by regulating APP maturation and transport to sites where Aβ protein is generated. This study clarifies the mechanisms through which Cerebrolysin might reduce Aβ production and deposition in AD and further supports the importance of this compound in the potential treatment of early AD. © 2006 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jnr.20818

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 88

Metadata

Authors
Rockenstein, E., Torrance, M., Mante, M., Adame, A., Paulino, A., Rose, J. B., Crews, L., Moessler, H., & Masliah, E.
Venue
Journal of Neuroscience Research
Publisher
Wiley
Published
2006-03
Volume
83
Issue
7
Pages
1252-1261
ISSN
  • 0360-4012 (ISSN-L)
  • 1097-4547
OpenAlex
W2140665706
Cited by
88
References
17
FWCI
3.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.